Interleukin‐27 in Rheumatic Diseases: Friend or Foe? Comment on the Article by Pickens Et Al

Feng‐Lai Yuan,Xia Li,Jun‐Ming Sun,Ruirong Xu
DOI: https://doi.org/10.1002/art.30495
2011-01-01
Abstract:,Pickens et al confirmed in vivo that injection of adenoviralinterleukin-27 (IL-27) transcript into the ankles of mice withcollagen-induced arthritis (CIA) attenuates joint inflamma-tion, synovial lining thickness, bone erosion, and leukocytemigration (1). Additionally, IL-27 treatment resulted in re-duced IL-1 and IL-6 production in mice with CIA. Moreover,IL-27 suppressed Th17 cell differentiation as well as down-stream IL-17 target genes, leading to decreased IL-17–mediated monocyte recruitment and angiogenesis, possiblythrough reduction of neutrophil and monocyte chemokines.They concluded that IL-27 may therefore be a promising targetfor therapeutic intervention to control disease in patients withrheumatoid arthritis (RA) (1).This interesting study provides valuable data on therole of IL-27 in RA. In fact, another study also demonstratedthat administration of IL-27 could attenuate CIA developmentat the onset of disease, by suppression of IL-17 and IL-6synthesis (2). Further, Rajaiah et al (3) showed that treatmentwith exogenous IL-27 successfully controlled arthritis-relatedinflammation and inhibited mediators of inflammation, angio-genesis, cell survival, apoptosis, and tissue damage in adjuvant-induced arthritis (AIA), by reducing matrix metalloproteinase9 (MMP-9) activity, vascular endothelial growth factor secre-tion, and phosphorylated Akt.However, the available data seem to be contro-versial. In several previous studies, IL-27 was detected inthe synovial membrane and synovial fluid of patients withRA and was reported to induce a Th1 immune responseandsusceptibilitytoproteoglycan-inducedarthritis(4).Consis-tent with these findings, anti–IL-27 antibody treatment orIL-27 receptor knockout has been found to suppress ongoingsevere inflammation and proinflammatory cytokine produc-tion in AIA (5). Moreover, recently published data suggestedthat IL-27 could stimulate other nonimmune cell targets,such as fibroblast-like synoviocytes (FLS), in the joints andinduce the expression of adhesion molecules on the cell sur-face of FLS and the release of chemokines and MMP-1 in RAFLS (6,7).Overall, based on immunologic evaluations it appearsthat IL-27 exerts profound antiinflammatory effects in RAmodels (“friend”) but at the same time plays a proinflamma-tory role in rheumatic diseases (“foe”). In order to ascertainthe exact mechanisms of action of IL-27 in rheumatic diseasesanddeterminewhetheritistrulyafriendorfoe,furtherstudieswith large sample sizes and precise methodology are needed,especially in human systems.
What problem does this paper attempt to address?